Phase 1/2 Trials
DMT Therapy
DMT (dimethyltryptamine) is a powerful psychedelic being studied for depression and end-of-life anxiety. Its short duration of action (15-30 minutes) makes it potentially more practical for clinical settings.
50Clinical Trials
2Companies
1Legal States
FDA StatusPhase 1/2 Trials
Legal PathwayFDA approval pathway (federal)
Also Known Asdimethyltryptamine, N,N-DMT, spirit molecule
Legal Status by State
View full legal tracker →Legal
Decriminalized
Pending
No Legislation
Decriminalized1
CO
Clinical Trials
6 trials currently recruiting
Phase 19
Phase 26
Phase 35
Active, Not Recruiting·N/A·Other
Pediatric Spinal Muscular Atrophy (SMA) China Registry
Biogen
Muscular Atrophy, Spinal
Unknown·Phase 1·Other
Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)
Hospital Universitario San Ignacio
Neoplasm, StomachGastric Neoplasms MalignantPancreatic Neoplasms+6 more
Completed·Phase 3·DMT
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Genentech, Inc.
Multiple Sclerosis, Relapsing-Remitting
Completed·N/A·Other
Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies
Novartis
Multiple Sclerosis
Terminated·N/A·Other
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
Biogen
Multiple Sclerosis (MS)
Completed·N/A·DMT
Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
University Hospital, Caen
C10.114.375.500
Companies & Research
Organizations developing DMT-based therapies